Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00416468 · ClinicalTrials.gov registry record · Phase 1

Bioavailability of Aliskiren and Valsartan Combined as a Single Tablet vs. the Same Medications Given Separately to Healthy Subjects.

A Phase 1 study, sponsored by Novartis.

Completed
Registry status
Phase 1
Development phase
32
Enrollment target

NCT00416468 is a Phase 1 study that has completed, run by Novartis. The registered enrollment target is 32 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00416468, a Phase 1 study, has completed, sponsored by Novartis.

COMPLETED
Registry status
Phase 1
Development phase
32 participants
Enrollment target

Study Summary

This study will assess the bioavailability of aliskiren and valsartan as a single tablet compared to the same doses of the two drugs given as two separate tablets in healthy subjects.

Interventions

  • DRUG Valsartan
  • DRUG Aliskiren

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2006-11
Phase Phase 1

Sponsor

Novartis

265 total trials

What the Registry Record Tells You About NCT00416468

The ClinicalTrials.gov registry entry for NCT00416468 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Valsartan is the first listed.

NCT00416468 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00416468 about?

NCT00416468 is a clinical study titled "Bioavailability of Aliskiren and Valsartan Combined as a Single Tablet vs. the Same Medications Given Separately to Healthy Subjects.". This study will assess the bioavailability of aliskiren and valsartan as a single tablet compared to the same doses of the two drugs given as two separate tablets in healthy subjects.

What is the current status of trial NCT00416468?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2006-11.

What interventions are being tested in trial NCT00416468?

The interventions under investigation include: Valsartan (DRUG), Aliskiren (DRUG).

Who is sponsoring clinical trial NCT00416468?

This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.